Key result
Targeted immunomodulation strategies, including low-dose interleukin-2 and immune checkpoint blockade, offer promising means to recalibrate immunity toward tissue repair following cardiac injury.
Why the study?
Cardiovascular injury initiates a temporally regulated immune cascade, but shifting therapy from non-specific immunosuppression to adaptive, stage-specific immunomodulation requires synthesizing recent mechanistic and omics insights.
Design
Review
Authors
Loading...
Proposed precision immunotherapy framework warrants clinical investigation; leaves open whether stage-specific immunomodulation improves cardiac outcomes.
This review provides a translational perspective on utilizing targeted immunomodulatory therapies, such as low-dose interleukin-2 and immune checkpoint blockade, to promote tissue repair after cardiac injury.
Liu et al. (2025) conducted a review in Cardiac injury. Targeted immunomodulation strategies, including low-dose interleukin-2 and immune checkpoint blockade, offer promising means to recalibrate immunity toward tissue repair following cardiac injury.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: